MEME KANSERİ GELİŞİMİNDEKİ PROGNOSTİK FAKTÖRLER: ERKEN VE GEÇ EVRE KANSERLERİN KARŞILAŞTIRILMASI

Giriş: Meme Kanseri, dünya çapında kadınlarda görülen en sık kanser olmakla birlikte aynı zamanda kansernedeniyle ölümün de en sık nedenidir. Meme kanserinde erken tanı hayat kurtarıcıdır. Tanı anında hastalarınerken veya geç dönem tümöre sahip olduğunun ön görülmesi tedaviyi daha iyi yönlendirecektir. Bu çalışmanınamacı meme kanseri olan hastalarda evreye göre çeşitli klinik, patolojik özelliklerin değişimin değerlendirilmesidir.Gereç ve Yöntem: Ocak 2010-Ocak 2020 yılları arasında takip edilen, toplam 798 Meme kanseri tanılı hastaçalışmaya dahil edildi. Bilinen risk faktörlerinden olan; cinsiyet, yaş, vücut kitle indeksi, sigara kullanımı, alkolkullanımı, yağlı tip beslenme, menopoz durumu, menarş yaşı, gebelik, doğum ve emzirme durumu,ailehikayesi,önceki meme hastalığı hikayesi, daha önce meme kanseri tanısı, oral kontraseptif ilaç kullanımı, hormonreplasman tedavisi hikayesi, mamografide dens meme dokusu olma durumu ve diyabet varlığı meme kanserikonsey formlarından ve hasta dosyalarından retrospektif olarak taranıp,kaydedildi.Bulgular: Hastaların 528’i (%66.2) erken evre ve 270’i (%33.8) ileri evre meme kanseri grubunda idi. İnvazifmeme kanseri erken evre tümörlü hastaların %80.6’sında (n=426) ve ileri evre tümörlerin %70.7’inde (n=200)mevcuttu. İnflamatuvar tipte meme kanseri erken evre kanseri olan hastalar arasında yoktu ancak ileri evretümörü olan hastaların 4’ünde (%1.7) mevcuttu (p

THE PROGNOSTIC FACTORS IN BREAST CANCER DEVELOPMENT: COMPARISON OF EARLY AND ADVANCED STAGE

Introduction: Breast cancer is globally the most frequent cancer among women and it is the most frequent cause of cancer related death. Early diagnosis of breast cancer is life saving. Prediction of the stage of the tumor at the diagnosis will help the management of these patients. The aim of the present study is to evaluate the clinical and pathologic characteristics of patients with breast cancer according to the stage of the disease. Material and Method: From January 2010 to January 2020, a total of 798 patients with breast cancer who were treated in our institute were included in the study. Gender, age, BMI, parity, births, breast feeding status, family history, previous breast disease, previous breast cancer diagnosis, oral contraceptive or hormonal replacement therapy use, the breast pattern in mammography, presence of diabetes were retrospectively analyzed from the patient database. Results: Among the patıents 528 (66.2%) were early and 270 (33.8%) patients were advanced stage breast cancers. Invasive breast cancer was present in 80.6% (n=426) and 70.7% (n=200) of the patients with early and late stage breast cancer; respectively. Inflammatory breast cancer was not present in early stage breast cancer patients and was present in 4 patients (1.7%) with advanced stage breast cancer (p

PDF

___

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65(2):87-108.
2. Donepudi MS, Kondapalli K, Amos SJ, Venkanteshan P. Breast cancer statistics and markers J Cancer Res Ther. 201;10(3):506-11.
3. Sondik EJ. Breast cancer trends.Incidence, mortality, and survival. Cancer 1994;74(3 Suppl):995-9.
4. Garfinkel L, Boring CC, Heath CW Jr. Changing trends.An overview of breast cancer incidence and mortality. Cancer 1994;74(1 Suppl):222-7.
5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69(1):7-34.
6. Kohler BA, Sherman RL, Howlader N,Jemal A, Ryerson AB, Henry KA et al. Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State. J Natl Cancer Inst. 2015;107(6):djv048.
7. de Gelder R, Heijnsdijk EA, Fracheboud J, Draisma G, de Koning HJ. The effects of population-based mammography screening starting between age 40 and 50 in the presence of adjuvant systemic therapy.Int J Cancer 2015;137(1):165-72.
8. Tabár L, Dean PB, Chen TH, Yen AM, Chen SL, Fann JCet al. The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. Cancer 2019;125(4):515-23.
9. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70(1):7-30.
10. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67(1):7-30.
11. Brewer HR, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ. Family history and risk of breast cancer: an analysis accounting for family structure. Breast Cancer Res Treat 2017;165(1):193-200.
12. Slattery ML, Kerber RA. A comprehensive evaluation of family history and breast cancer risk.The Utah Population Database. JAMA 1993;270(13):1563-8.
13. Heron DE, Komarnicky LT, Hyslop T, Schwartz GF, Mansfield CM. Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease. Cancer 2000;88(12):2739-50.
14. Dall GV, Britt KL. Estrogen effects on the mammary gland in early and late life and breast cancer risk. Front Oncol 2017;7:110.
15. Horn J, Åsvold BO, Opdahl S, Tretli S, Vatten LJ. Reproductive factors and the risk of breast cancer in old age: a Norwegian cohort study. Breast Cancer Res Treat 2013;139(1):237-43.
16. Key TJ, Appleby PN, Reeves GK, Travis RC, Alberg AJ, Barricarte A et al. Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol 20130;14(10):1009-19.
17. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362(9382):419-27.
18. Narod SA. Hormone replacement therapy and the risk of breast cancer. Nat Rev ClinOncol 2011;8(11):669-76.
19. Fahlén M, Fornander T, Johansson H, Johansson U, Rutqvist LE, Wilking N et al. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer 2013;49(1):52-9.
20. Hamajima N, Hirose K, Tajima K, Rohan T, Calle EE, Heath CW Jr et al. Collaborative Group on Hormonal Factors in Breast Cancer.Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer 2002;87(11):1234-45.
21. Makarem N, Chandran U, Bandera EV, Parekh N. Dietary fat in breast cancer survival. Annu Rev Nutr 2013;33:319-48.
22. Knight JA, Fan J, Malone KE, John EM, Lynch CF, Langballe R et al. Alcohol consumption and cigarette smoking in combination: A predictor of contralateral breast cancer risk in the WECARE study. Int J Cancer 2017;141(5):916-24.
23. Gaudet MM, Carter BD, Brinton LA, Falk RT, Gram IT, Luo J et al. Pooled analysis of active cigarette smoking and invasive breast cancer risk in 14 cohort studies.Int J Epidemiol 2017;46(3):881-93.
24. Hutchinson WB, Thomas DB, Hamlin WB, Roth GJ, Peterson AV, Williams B. Risk of breast cancer in women with benign breast disease. J Natl Cancer Inst 1980;65(1):13-20.
25. Kodlin D, Winger EE, Morgenstern NL, Chen U. Chronic mastopathy and breast cancer. A follow-up study. Cancer 1977;39(6):2603-7.
26. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312(3):146-51.
27. Dupont WD, Page DL. Breast cancer risk associated with proliferative disease, age at first birth, and a family history of breast cancer. Am J Epidemiol 1987;125(5):769-79.
28. Wolfe JN. Breast patterns as an index of risk for developing breast cancer. AJR Am J Roentgenol 1976;126(6):1130-7.
29. Saftlas AF, Szklo M. Mammographic parenchymal patterns and breast cancer risk. Epidemiol Rev 1987;9:146-74.
30. Gravelle IH, Bulstrode JC, Wang DY, Bulbrook RD, Hayward JL. The relation between radiographic features and determinants of risk of breast cancer.Br J Radiol. 1980;53(626):107-13.